- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Lilly's Mounjaro wins US label expansion for cardiovascular risk reduction | ||
| Fr | FDA approves Priovant's rare autoimmune therapy Lisraya in indication first | ||
| Fr | AusperBio raises $120m to progress hepatitis B therapies | ||
| Fr | FDA to review Kowa Pharmaceuticals' NDA for glaucoma eye drop K-911 | ||
| Do | SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race | ||
| Do | ESC 2026: True impact of poor medicine adherence laid bare in hypertensive patients | ||
| Do | FDA grants RPDD to ReviR's RTX-117 for CMT | ||
| Do | ViiV Healthcare's Tivicay PD gains FDA approval for paediatric HIV therapy | ||
| Mi | RevMed's pancreatic cancer drug breezes through with swift approval | ||
| Mi | Metsera backers establish new biotech armed with China-licensed immunology asset | ||
| Mi | Jazz secures FDA approval for Ziihera in advanced HER2+ GEA | ||
| Mi | ESC 2026: Common pharma excipient linked to uptick in cardiovascular risk | ||
| Mi | McKesson to acquire Precision Medicine Group for $2.25bn | ||
| Di | J&J's Imaavy secures expanded US approval in rare blood disorder | ||
| Di | FDA places clinical hold on Regenxbio's RGX-121 in MPS II trial | ||
| Di | GSK snags Japanese approval for first hepatitis B functional cure, Hibsago | ||
| Di | Lundbeck's asedebart receives EC orphan designation in Cushing's syndrome | ||
| Di | Takeda's Orzeyful secured Japan MHLW approval for narcolepsy type 1 | ||
| Mo | Roche outlays $2.3bn for Hanmi's non-GLP-1 obesity candidate | ||
| Mo | Analysts praise intismeran's landmark Phase III win, look to further data | ||
| Mo | Gossamer Bio announces $250m in funding to advance seralutinib | ||
| Mo | Johnson & Johnson's multiple myeloma treatment secures EC approval | ||
| 21.08. | Roche commits $750m to double Oregon-based US manufacturing capacity | ||
| 21.08. | Eli Lilly's weekly insulin jab Onswik set for NHS use if approved | ||
| 21.08. | WellSpan and Johns Hopkins renew partnership for advanced cancer care access |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.